Noninvasive Prenatal Screening of Fetal Aneuploidy without Massively Parallel Sequencing. - PubMed - NCBI

Noninvasive Prenatal Screening of Fetal Aneuploidy without Massively Parallel Sequencing. - PubMed - NCBI

Clin Chem. 2017 Feb 14. pii: clinchem.2016.266247. doi: 10.1373/clinchem.2016.266247. [Epub ahead of print]

Noninvasive Prenatal Screening of Fetal Aneuploidy without Massively Parallel Sequencing.

Xu C1,2, Wang T3, Liu C4, Li H3, Chen X4, Zhu H4, Chen S1,2, Xin Q4, Tao J4, Huang L4, Jiang Z5.

Author information

Abstract

BACKGROUND:

Noninvasive prenatal screening (NIPS) using plasma cell-free DNA has gained tremendous popularity in the clinical assessment of fetal aneuploidy. Most, if not all, of these tests rely on complex and expensive massively parallel sequencing (MPS) techniques, hindering the use of NIPS as a common screening procedure.

METHODS:

We have developed and optimized an MPS-independent noninvasive genetic test that can rapidly detect fetal aneuploidy at considerably lower costs. We used the high-throughput ligation-dependent probe amplification (HLPA) assay with standard z score statistics to identify the minute copy number change of targeted chromosomal regions. HLPA was modified from multiplex ligation-dependent probe amplification to allow quantification of up to 200 genomic loci in a single multiplex PCR. As a proof of principle, we conducted Down syndrome screening in 1182 women with singleton pregnancies [maternal age (SD): 32.7 (4.6)] using whole-genome sequencing-based NIPS and our method.

RESULTS:

Nineteen fetuses with trisomy 21 were detected by both methods and confirmed by karyotyping of amniotic fluid. Overall, our method showed 100.0% sensitivity (19/19) and 99.7% specificity (1076/1079) in trisomy 21 screening, generating a positive predictive value of 86.4% (19/22) and a 7.1% (84/1182) no-call rate.

CONCLUSIONS:

Our technique potentially opens new avenues for the development of inexpensive, yet effective, prenatal aneuploidy tests. The simplicity and accuracy of this method make it a good candidate for clinical implementation as a standard screening procedure.

© 2016 American Association for Clinical Chemistry.

PMID:

 

28196921

 

DOI:

 

10.1373/clinchem.2016.266247

From From Genomics & Health Impact Scan Database

This database includes published scientific literature on evidence-based translation of genomic discoveries into improved health care and disease prevention that have a potential impact on population health.

---

• Noninvasive Prenatal Screening of Fetal Aneuploidy without Massively Parallel Sequencing.  
  Xu Chenming et al. Clinical chemistry 2017 Feb
• Noninvasive prenatal testing: more caution in counseling is needed in high risk pregnancies with ultrasound abnormalities.  
  Oneda Beatrice et al. European journal of obstetrics, gynecology, and reproductive biology 2016 May 20072-5
• The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population.  
  Palomaki Glenn E et al. Genetics in medicine : official journal of the American College of Medical Genetics 2017 Jan
• Clinical experience from Thailand: noninvasive prenatal testing as screening tests for trisomies 21, 18 and 13 in 4736 pregnancies.  
  Manotaya S et al. Prenatal diagnosis 2016 Mar 36(3) 224-31
• Patient Perception of Negative Noninvasive Prenatal Testing Results.  
  Wittman A Theresa et al. AJP reports 2016 Oct 6(4) e391-e406

more